anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Mesenchymal stem cell (MSCs) therapy, as a rapidly developing area of medicine, holds great promise for the treatment of a variety of medical conditions. MSCs are multipotent stem cells that can be isolated from various tissues and could self-renew and differentiate. They secrete cytokines and trophic factors that create a regenerative microenvironment and have immunomodulatory properties. Although clinical trials have been conducted with MSCs in various diseases, concerns regarding the possibility of malignant transformation of these cells have been raised. The studies showed a higher rate of hematological malignancy and carcinogenesis in experimental models after MSC transplantation. The mechanisms underlying malignant transformation of MSCs are complex and not fully understood, but they are believed to involve the presence of special signaling molecules and alterations in cell behavior regulation pathways. Possible pathways that lead to MSCs' oncogenic transformation occur through two mechanisms: spontaneous and stimulated malignant transformation, including cell fusion, fusion proteins, and the tumor microenvironment. MSC-based therapies have the potential to revolutionize medicine, and addressing the issue of malignancy is crucial to ensure their safety and efficacy. Therefore, the purpose of the present review is to summarize the potential mechanisms of the malignant transformation of MSCs. [Figure: see text].
The management of overactive bladder (OAB) in women encompasses a range of strategies, from behavioral modifications to pharmacotherapy and nerve stimulation techniques. This prospective, randomized, controlled trial evaluates the efficacy of the combination of TTNS and mirabegron in symptom improvement over three months in women diagnosed with OAB. The study was designed as a randomized controlled trial. A total of 40 patients were prospectively randomized into two groups. Twenty patients in the combination group accepted TTNS and mirabegron therapy, and the other 20 patients as control only accepted mirabegron therapy. Primary outcomes were changes from baseline in the lower urinary tract symptoms. The severity of symptoms and quality of life (QoL) were assessed using the validated OAB questionnaire (OAB-q). TTNS reduced the clinical symptoms of OAB, and the difference was statistically significant at all study sites (p < 0.05). Regarding secondary outcomes, the OAB-q symptom bother score was lower in the combination group than in the mirabegron group (p < 0.05). The OAB-q score in the combination group was statistically superior to that in the mirabegron group (p < 0.05). The incidence of complications was not statistically significant between the two groups.The combination of TTNS and mirabegron represents a promising therapeutic strategy for women with overactive bladder, significantly improving symptoms and quality of life with a favorable safety profile. Further research with a larger sample size and long-term follow-up is warranted to confirm these findings and explore the underlying mechanisms of this combination therapy's efficacy.
A health monitoring (HM) computing device for monitoring patient vitals in real time is provided. The HM computing device includes at least one processor in communication with at least one memory device. The at least one processor is programmed to receive patient data from a plurality of patient computer devices associated with a plurality of patients. The at least one processor is also programmed to, for each patient of the plurality of patients, compare the received patient data corresponding to the patient to a reference model tailored to the corresponding patient. The at least one processor is also programmed to determine, based upon the comparisons, at least one status category for each of the plurality of patients. Moreover, the at least one processor is further programmed to generate and transmit instructions for displaying a first graphical user interface to a healthcare provider computer device associated with the healthcare provider.
FIELD: apiculture. SUBSTANCE: method involves preparing bee glue by processing it to powder state; preparing mixture of bee glue and solvent; providing extraction with following filtering and concentrating of obtained extract of bee glue. Prior to extraction process, solvent is poured into prepared bee glue and mixture is infused. Extraction process is conducted at solvent boiling temperature. Upon extraction, hot mixture is filtered and obtained filtrate is cooled and repeatedly filtered, with following separation of liquid bee glue extract and bee glue wax and distillation of solvent from liquid extract. Infusion is performed for time period required for diffusion of solvent deep into powdered bee glue. Bee glue and solvent ratio is chosen such that, before extraction process after infusion, the amount of solvent remaining above bee glue surface is not less than amount sufficient for preventing from contact with air. Also, before extraction, powdered bee glue is exposed to supersonics. To obtain extract, native as well as secondary bee glue is used, for example, that obtained after preparing of aqueous or oil extract. EFFECT: increased yield of biologically active substances, reduced consumption of solvent and reduced time for obtaining final product. 7 cl, 2 ex
This is an open-label (all people know the identity of the intervention), prospective (study following participants forward in time), single-arm, multi-center (conducted in more than 1 center), interventional pilot study of the effects of a combined dietary and exercise intervention on glucose metabolism. The duration of this study will be 6 months and will include following visits: Baseline, Week 4, Week 12, and Week 24. Dietary compliance will be evaluated with a 3-day food record and during weekly telephone conversations and face-to-face visits with a dietician. Exercise compliance will be measured using an exercise log presented to the co-ordinator at the end of each month. Primarily, participants with insulin resistance will be assessed by Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) of greater than 1 at 6 months. Participants' safety and tolerability will be monitored throughout the study.
* Sandostatin Injection may be administered subcutaneously or intravenously. Pain with subcutaneous administration may be reduced by using the smallest volume that will deliver the desired dose. Sites should be rotated in a systematic manner.
  * Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if particulates and/or discoloration are observed. Sandostatin Injection is not compatible in Total Parenteral Nutrition solutions because of the formation of a glycosyl octreotide conjugate which may decrease the efficacy of the product.
  * Sandostatin Injection may be diluted in volumes of 50 mL to 200 mL and infused intravenously over 15 to 30 minutes or administered by intravenous (IV) push over 3 minutes. In emergency situations (e.g., carcinoid crisis), it may be given by rapid bolus.
  * Assess total and/or free T4 levels at baseline and periodically during chronic Sandostatin therapy.
BACKGROUND: Intravenous immunoglobulin (IVIg) and plasmapheresis (PLEX) are recommended in moderate to severe Guillain-Barré Syndrome (GBS), but there is paucity of studies evaluating its effect on nerve conduction studies (NCS). We report the effect of IVIg and PLEX on the NCS parameters and clinical outcomes compared to natural course (NC) of GBS patients.
METHOD: Moderate to severe GBS patients were included based on clinical, cerebrospinal fluid, and NCS finding. Six motor and sensory nerves were evaluated at admission, one month and 3 months, and NCS subtyping was done. Axonal and demyelination burden in motor nerves and early reversible conduction block (ERCB) were noted. Patients receiving IVIg, PLEX or on NC were noted. Outcome was defined at 3 months into complete, partial and poor using a 0-6 GBS Disability Scale (GBSDS).
RESULT: Seventy-two patients were included, whose median age was 36 years and 22(30.6 %) were females. 44 patients received IVIg, 9 PLEX and 19 were in NC, and they had comparable peak disability. AIDP was the dominant subtype at admission (58.3 %), which remained so at 3 months (50 %). The shift of subtypes was the highest from the equivocal group followed by AMAN and the least from AIDP. IVIg and PLEX group had more reduction in axonal burden and had ERCB compared to NC. 33(44 %) patients had complete recovery, and 40(55.5 %) patients had concordance in clinical and neurophysiological outcome.
CONCLUSION: Transition of GBS subtype may occur at follow-up from all the subtypes, the highest from the equivocal and the lowest from the AIDP group. IVIg/PLEX treatment may help in reducing conduction block and axonal burden.
Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 60mg/m2.
The waiting list control group participants will be controlled for time and assessed during the first 7-week period. Participants will have no contact with the study team during the waiting period. Immediately after the waiting period, they will receive the internet-based intervention with the experimental group.
Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).
PURPOSE:To provide an anticancer agent substantially not having any adverse effect, extremely safe for living bodies and highly effective for especially leukemia, etc., by containing as an active ingredient a polymeric decomposition product extract having a specific mol. wt. and prepared by decomposing protein contained in a fish with an enzyme. CONSTITUTION:The protein of a fish is decomposed with a self-decomposing enzyme and/or a protein-decomposing enzyme contained in the fish and the decomposition product is purified by an ultrafiltration method, a gel filtration method, etc., using a column, a high-performance liquid chromatography, etc., to provide a polymeric decomposition product extract having a mol. wt. of 50000-300000, preferably 57,400-220,000. The extract has a cell-injuring activity, cancer cell multiplication-suppressing activity and an immune-activating activity against the cancer cells and the extract prepared from only the visceral portion of the fish as a raw material is especially preferable. The minimal effective dose of the extract is 25 mg/kg in a case of oral administration and 10 mg/kg in a case of intravenous injection.
This group comprising 5 healthcare units equipped with a Family Health Strategy. Patients were seen by coordinating nurses who used techniques and supplies with which they were already familiar. They had no protocol in place.
Methods are provided for enhancing regeneration of nerves, e.g. peripheral nerves. The method comprises administering to the subject, at or near the site of the peripheral nerve injury, an effective amount of a composition comprising an agent that promotes regeneration of the peripheral nerve by stimulating hedgehog signaling. Agents of interest include a smoothened agonist. The agent may be delivered in a fibrin-based hydrogel, which is optionally 3D printed and may be provided as a nerve wrap. In some embodiments administration is provided prior to injury, e.g. prior to surgery.
In Japan, subsidies from local and national government programs for HPV vaccination of girls aged 13-16 began in 2010. By 2013, HPV vaccines were being used routinely for vaccinating girls aged 12-16 as part of its national immunization program. However, in June of 2013, in response to reports of possible adverse reactions to the vaccine, Japan's Ministry of Health, Labor, and Welfare (MHLW) announced a 'temporary suspension' of its governmental recommendation for HPV vaccination. The vaccination rate quickly dropped from 70 % of age-eligible girls to almost zero. It was not until 2021 that the government's recommendation suspension finally ended. The efficacy and safety of the HPV vaccine is now well documented, yet Japan has failed to reestablish any credible level of HPV vaccination. The World Health Organization (WHO) warned that Japan's HPV vaccination debacle was likely to result in real harm to the girls who lacked its protection; something we have already demonstrated with real-world data. To reinvigorate the HPV vaccination program in Japan to its prior levels, in the face of the current high level of HPV vaccine hesitancy, we will have to address the irrationality of human decision-making pointed out by behavioral economics. The Japanese government must act expeditiously to promote stronger cervical cancer control measures.
Gummy stem blight (GSB), a widespread disease causing great loss to cucurbit production, has become a major threat to melon cultivation. However, the melon-GSB interaction remains largely unknown. Here, full-length transcriptome and widely targeted metabolome were used to investigate the defence responses of resistant (PI511089) and susceptible (Payzawat) melon accessions to GSB pathogen infection at 24 h. The biosynthesis of secondary metabolites and MAPK signalling pathway were specifically enriched for differentially expressed genes in PI511890, while carbohydrate metabolism and amino acid metabolism were specifically enriched in Payzawat. More than 1000 novel genes were identified and MAPK signalling pathway was specifically enriched for them in PI511890. There were 11 793 alternative splicing events involving in the defence response to GSB. Totally, 910 metabolites were identified in Payzawat and PI511890, and flavonoids were the dominant metabolites. Integrated full-length transcriptome and metabolome analysis showed eriodictyol and oxalic acid were the potential marker metabolites for GSB resistance in melon. Moreover, posttranscription regulation was widely involved in the defence response of melon to GSB pathogen infection. These results not only improve our understanding on the interaction between melon and GSB, but also facilitate the genetic improvement of melon with GSB resistance.
Recent empirical evidence suggests that gut dysbiosis is one of the negative health outcomes potentially associated with chronic consumption of some food additives. In this context, the present study aimed at analyzing the disclosure of food additives associated with gut dysbiosis in the labels of products commercialized in the Uruguayan market. A cross-sectional survey of packaged products commercialized in nine supermarkets was conducted between August and September 2021. All packaged processed and ultra-processed products available in each data collection site were surveyed using a cellphone app. The information available on the labels was manually extracted and the disclosure of food additives was analyzed using a computer assisted approach. Results showed that 38.1% of the products disclosed at least one food additive associated with gut dysbiosis. Disclosure was most frequent in ice-cream and popsicles, beverages, meat products and analogues, desserts, and fats, oils and fat and oil emulsions. Potassium sorbate was the individual additive associated with gut dysbiosis most frequently disclosed on the labels, followed by mono- and di-glycerides of fatty acid, sucralose, carboxymethylcellulose, acesulphame potassium, carrageenan, and sodium benzoate. These food additives frequently co-occurred and network analysis enabled the identification of patterns of co-occurrence. Taken together, results from the present work suggest the need to conduct additional research to assess the intake of food additives associated with gut dysbiosis at the population level, as well as to evaluate potential synergistic effects of food additives.
The aim of this study was to investigate whether the protective effect of 2-deoxyglucose (2-DG) on lung ischemia/reperfusion (I/R) injury is mediated by inhibiting nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3)-mediated pyroptosis in rats. Male Sprague-Dawley rats were randomly divided into control group, 2-DG group, lung I/R injury group (I/R group) and 2-DG+I/R group. 2-DG (0.7 g/kg) was intraperitoneally injected 1 h prior to lung ischemia. The tissue structure was measured under light microscope. Lung injury parameters were detected. The contents of malondialdehyde (MDA), myeloperoxidase (MPO) and lactate were determined by commercially available kits. ELISA was used to detect the levels of IL-1β and IL-18. Western blot, qRT-PCR and immunofluorescence staining were used to measure the expression changes of glycolysis and pyroptosis related indicators. The results showed that there was no significant difference in the parameters between the control group and the 2-DG group. However, the lung injury parameters, oxidative stress response, lactic acid content, IL-1β, and IL-18 levels were significantly increased in the I/R group. The protein expression levels of glycolysis and pyroptosis related indicators including hexokinase 2 (HK2), pyruvate kinase 2 (PKM2), NLRP3, Gasdermin superfamily member GSDMD-N, cleaved-Caspase1, cleaved-IL-1β and cleaved-IL-18, and the gene expression levels of HK2, PKM2 and NLRP3 were markedly up-regulated in the I/R group compared with those in the control group. The expression of HK2 and NLRP3 was also increased detected by immunofluorescence staining. Compared with the I/R group, the 2-DG+I/R group exhibited significantly improved alveolar structure and inflammatory infiltration, reduced lung injury parameters, and decreased expression of glycolysis and pyroptosis related indicators. These results suggest that 2-DG protects against lung I/R injury possibly by inhibiting NLRP3-mediated pyroptosis in rats.
BACKGROUND: The aim of the study was to assess the relationship between prevalence of kidney stones (KS) and the oxidative balance score (OBS).
METHODS AND MATERIALS: Participants who participated in the KS questionnaire was extracted from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018. A series of covariates were also obtained. Weighted adjusted logistic regression was performed to investigate the association of KS with OBS. Dose-response relationship between KS and OBS was assessed by restricted cubic spline.
RESULTS: In the fully adjusted model, we discovered that the risk of KS decreased by 3% with each OBS unit raised (OR = 0.97, 95% CI: 0.95-0.99, P = 0.01). In the OBS subgroups, in contrast to the lowest quartile OBS, the higher quartile OBS was correlated to the decreased risk of KS prevalence (Q3 vs Q1: OR = 0.7, 95% CI: 0.49-0.99, P = 0.04; Q4 vs Q1: OR = 0.66, 95% CI: 0.44-0.99, P = 0.04), and the results maintained relative stability across three models. We also found that the risk of population with KS was negatively linked with each unit increase in dietary OBS (OR = 0.97, 95% CI: 0.95-0.99, P = 0.005). Finally, we detected that there was a linear association between OBS and the risk of KS prevalence (P non-linear > 0.05).
CONCLUSION: The study discovered that OBS that comprehensively reflects an individual's overall burden of oxidative stress was negatively related to the risk of KS, and can be utilized as an important indicator for assessing the risk of KS.
Renal Toxicity

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy was usually followed by recovery to the pretreatment state.

No information is available from controlled clinical studies regarding the use of NAPROSYN Suspension in patients with advanced renal disease. The renal effects of NAPROSYN Suspension may hasten the progression of renal dysfunction in patients with preexisting renal disease.

Correct volume status in dehydrated or hypovolemic patients prior to initiating NAPROSYN Suspension. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of NAPROSYN Suspension [see Drug Interactions (7)]. Avoid the use of NAPROSYN Suspension in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If NAPROSYN Suspension is used in patients with advanced renal disease, monitor patients for signs of worsening renal function.

Hyperkalemia   
Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.
FIELD: medicine, chemical-pharmaceutical industry. SUBSTANCE: invention relates to method of preparing pectin polysaccharides from plant raw material. Plant raw material is treated with formalin aqueous solution, kept in acidified water at pH 3.8-4.2 and 45-52 C to remove calcium and magnesium bridges followed by extraction of pectin polysaccharides with ammonium oxalate aqueous solution. Then extract is evaporated, treated with 96% ethyl alcohol and lyophilized. Fresh-water flower plants, for example, any species of duckweed genus (Lemna spp.) or preliminary milled fresh above ground part of higher plants containing pectin polysaccharides, for example, common campion Oberna behen (L.) Ikonn (Silene vulgaris, Moench Garke) are used as plant raw material. EFFECT: high yield and purification degree of product. 5 cl, 2 tbl, 4 ex
Ceramic orthodontic brackets are bonded to teeth with dental adhesive. Each bracket has a silica-­containing layer on the tooth facing base of the bracket. A silanation layer is also applied to the base. The silanation layer is deposited from a solution containing a first silane coupling agent reactive with organic resin in the adhesive and a second silane coupling agent having a non-reactive organic group. Collectively the silanes occupy all of the silanation sites on the silica-containing substrate. By controlling the ratio of reactive and non-reactive silane coupling agents, the bond strength between the substrate and the adhesive can be controlled. A set of ceramic orthodontic brackets can have uniform force of removal by varying the proportions of silane coupling agents on the brackets.